The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MDS 2020 | Azacitidine treatment toxicities
Rena Buckstein
• 5 Mar 2020
Rena Buckstein, MD, FRCPC, Odette Cancer Research Program, Sunnybrook Research Institute, Toronto, Canada, discusses some of the toxicities associated with azacitidine in the treatment of higher-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.
